Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.02T
Market cap1.02T
Price-Earnings ratio
38.30
Price-Earnings ratio38.30
Dividend yield
0.61%
Dividend yield0.61%
Average volume
3.29M
Average volume3.29M
High today
$1,093.28
High today$1,093.28
Low today
$1,053.51
Low today$1,053.51
Open price
$1,060.01
Open price$1,060.01
Volume
2.65M
Volume2.65M
52 Week high
$1,149.10
52 Week high$1,149.10
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.02T, Eli Lilly(LLY) trades at $1,077.79. The stock has a price-to-earnings ratio of 38.30 and currently yields dividends of 60.7%.

On 2026-06-03, Eli Lilly(LLY) stock moved within a range of $1,053.51 to $1,093.28. With shares now at $1,077.79, the stock is trading +2.3% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 2.65M, compared to an average daily volume of 3.29M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,149.10 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,149.10 and a low of $623.78.

LLY News

Nasdaq 2h
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better

Key Points Eli Lilly's retatrutide seems even more effective than Zepbound. The drugmaker should continue riding the weight-loss tailwind. 10 stocks we like...

Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better
Seeking Alpha 4h
Lilly halving planned €2.3B investment in Germany: CEO

Eli Lilly (LLY) CEO Dave Ricks told German business daily Handelsblatt that his company will halve its initially planned €2.3B ($2.7B) investment in Germany as...

Lilly halving planned €2.3B investment in Germany: CEO
TipRanks 5h
Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analys...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

24/7 Wall St. 5h
Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn't one of them. Get them here FREE . Over recent months, a striking patter...

Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry
TipRanks 7h
‘Expect More Acquisitions,’ Says Eli Lilly’s Top Dealmaker

Eli Lilly’s (LLY) top dealmaker says that the pharmaceutical giant is likely to undertake more acquisitions as it pushes into new medicinal areas. Unlock trust...

The Wall Street Journal 9h
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

Eli Lilly and Ascidian Therapeutics to research and develop kidney-disease treatments. mike segar / Reuters Eli Lilly LLY -1.67 %decrease; red down pointing tr...

Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
CNBC 10h
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Key Points Eli Lilly's Jacob Van Naarden says Lilly is using the financial strength from its GLP-1 drugs like Mounjaro and Zepbound to fund its new dealmaking s...

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Nasdaq 14h
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Key Points Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene edi...

Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
TipRanks 1d
Eli Lilly issues data sharing ultimatum to hospitals, Fierce Healthcare reports

Eli Lilly (LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with its claims data reporting requirements int...

Nasdaq 1d
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Key Points VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offe...

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.